Activities of antimicrobial peptides and synergy with enrofloxacin against Mycoplasma pulmonis

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 2, 2007, Pages 468-474

  Fehri, Lina Fassi ^a   Wróblewski, Henri ^b   Blanchard, Alain ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALAMETHICIN; ENROFLOXACIN; GLOBOMYCIN; GRAMICIDIN S; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SURFACTIN;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM CONTAMINATION; CELL CULTURE; COLONY FORMING UNIT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG POTENTIATION; HELA CELL; IMMUNE SYSTEM; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOPLASMA FERMENTANS; MYCOPLASMA HYORHINIS; MYCOPLASMA PULMONIS; NONHUMAN; PRIORITY JOURNAL;

ALAMETHICIN; ANIMALS; ANTI-INFECTIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FLUOROQUINOLONES; HELA CELLS; HUMANS; MICE; MYCOPLASMA INFECTIONS; MYCOPLASMA PULMONIS; PEPTIDES, CYCLIC; TIME FACTORS;

EID: 33846618655     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01030-06     Document Type: Article

References (27)

1. Andres, E., and J. L. Dimarcq. 2004. Cationic antimicrobial peptides: update of clinical development. J. Intern. Med. 255:519-520.
2. Bébéar, C. M., and I. Kempt. 2005. Antimicrobial therapy and antimicrobial resistance, p. 535-568. In A. Blanchard and G. Browning (ed.), Mycoplasmas. Molecular biology, pathogenicity, and strategies for control. Horizon Bioscience, Norfolk, United Kingdom.
3. Béven, L., M. Le Henaff, C. Fontenelle, and H. Wróblewski. 1996. Inhibition of spiralin processing by the lipopeptide antibiotic globomycin. Curr. Microbiol. 33:317-322.
4. Béven, L., and H. Wróblewski. 1997. Effect of natural amphipathic peptides on viability, membrane potential, cell shape and motility of mollicutes. Res. Microbiol. 148:163-175.
5. Blanchard, A., and C. M. Bébéar. 2002. Mycoplasmas of humans, p. 45-71. In S. A. Razin and R. Herrmann (ed.), Molecular biology and pathogenicity of mycoplasmas. Kluwer Academic Plenum, New York, NY.
6. Boman, H. G. 2003. Antibacterial peptides: basic facts and emerging concepts. J. Intern. Med. 254:197-215.
7. Brogden, K. A. 2005. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol. 3:238-250.
8. Brown, K. L., and R. E. Hancock. 2006. Cationic host defense (antimicrobial) peptides. Curr. Opin. Immunol. 18:24-30.
9. Chambaud, I., H. Wróblewski, and A. Blanchard. 1999. Interactions between mycoplasma lipoproteins and the host immune system. Trends Microbiol. 7:493-499.
10. Dartois, V., J. Sanchez-Quesada, E. Cabezas, E. Chi, C. Dubbelde, C. Dunn, J. Granja, C. Gritzen, D. Weinberger, M. R. Ghadiri, and T. R. Parr, Jr. 2005. Systemic antibacterial activity of novel synthetic cyclic peptides. Antimicrob. Agents Chemother. 49:3302-3310.
11. Dev, I. K., R. J. Harvey, and P. H. Ray. 1985. Inhibition of prolipoprotein signal peptidase by globomycin. J. Biol. Chem. 260:5891-5894.
12. Duclohier, H., and H. Wróblewski. 2001. Voltage-dependant pore formation and antimicrobial activity by alamethicin and analogues. J. Membrane Biol. 184:1-12.
13. Eliopoulos, G., and J. R. Moellering. 1996. Antimicrobial combinations, p. 330-393. In V. Lorian (ed.), Antibiotics in laboratory medicine. Williams and Wilkins, Baltimore, MD.
14. Fassi Fehri, L., P. Sirand-Pugnet, G. Gourgues, G. Jan, H. Wróblewski, and A. Blanchard. 2005. Resistance to antimicrobial peptides and stress response in Mycoplasma pulmonis. Antimicrob. Agents Chemother. 49:4154-4165.
15. Frey, J. 2002. Mycoplasmas of animals, p. 73-90. In S. A. Razin and R. Herrmann (ed.), Molecular biology and pathogenicity of mycoplasmas. Kluwer Academic Plenum, New York, NY.
16. Hancock, R. E., and R. Lehrer. 1998. Cationic peptides: a new source of antibiotics. Trends Biotechnol. 16:82-88.
17. Hodge, L. M., and J. W. Simecka. 2002. Role of upper and lower respiratory tract immunity in resistance to Mycoplasma respiratory disease. J. Infect. Dis. 186:290-294.
18. Latorre, R., and O. Alvarez. 1981. Voltage-dependent channels in planar lipid bilayer membranes. Physiol. Rev. 61:77-150.
19. Marr, A. K., W. J. Gooderham, and R. E. W. Hancock. 2006. Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Curr. Opin. Pharmacol. 6:468-472.
20. Nir-Paz, R., M. C. Prevost, P. Nicolas, A. Blanchard, and H. Wróblewski. 2002. Susceptibilities of Mycoplasma fermentans and Mycoplasma hyorhinis to membrane-active peptides and enrofloxacin in human tissue cell cultures. Antimicrob. Agents Chemother. 46:1218-1225.
21. Odds, F. C. 2003. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 52:1.
22. Peypoux, F., J. M. Bonmatin, and J. Wallach. 1999. Recent trends in the biochemistry of surfactin. Appl. Microbiol. Biotechnol. 51:553-563.
23. Pragai, Z., H. Tjalsma, A. Bolhuis, J. M. van Dijl, G. Venema, and S. Bron. 1997. The signal peptidase II (Isp) gene of Bacillus subtilis. Microbiology 143:1327-1333.
24. Prenner, E. J., R. N. Lewis, and R. N. McElhaney. 1999. The interaction of the antimicrobial peptide gramicidin S with lipid bilayer model and biological membranes. Biochim. Biophys. Acta 1462:201-221.
25. Rebuffat, S., C. Goulard, B. Bodo, and M.-F. Roquebert. 1999. The peptaibol antibiotics from Trichoderma soil fungi; structural diversity and membrane properties. Recent Res. Dev. Org. Bioorg. Chem. 3:65-91.
26. Sander, P., M. Rezwan, B. Walker, S. K. Rampini, R. M. Kroppenstedt, S. Ehlers, C. Keller, J. R. Keeble, M. Hagemeier, M. J. Colston, B. Springer, and E. C. Bottger. 2004. Lipoprotein processing is required for virulence of Mycobacterium tuberculosis. Mol. Microbiol. 52:1543-1552.
27. Zasloff, M. 2002. Antimicrobial peptides of muticellular organisms. Nature 415:389-395.